Company: REVB
Filing Date: 2025-03-06
Form Type: 10-K
Source: 0000950170-25-034584
Chunk: 13

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-03-06
Form: 10-K
Item: Item 11
Chunk 13
---
 to our CFO, our only other non-PEO named executive officer, during each of the past two fiscal years, as well as our total stockholder return and net loss for each of the past two fiscal years.

    Year
     
    Summary Compensation Table Total for PEO(1)

    Compensation Actually Paid to PEO(2)(3)

    Average SummaryCompensation Table Total for Non-PEO Named Executive Officers(4)

    Average Compensation Actually Paid to Non-PEO Named Executive Officers(5)(6)

    Value of Initial Fixed $100 InvestmentBased On Total Shareholder Return(7)

    Net Loss(millions)(8)

    2024
     
    $
    813,226

    $
    813,226

    $
    564,006

    $
    564,006

    $
    0.23

    $
    (15.04
    )

    2023
     
    $
    649,250

    $
    649,250

    $
    479,141

    $
    479,141

    $
    3.07

    $
    (0.12
    )

(1)Amounts reported represent the Summary Compensation Table total for our CEO for each of the fiscal years presented. See “Executive Compensation—Summary Compensation Table.”

(2)Amounts reported represent compensation actually paid to our CEO for each of the fiscal years presented. The dollar amounts in this column do not reflect the actual amount of compensation earned by or paid to our CEO during the applicable fiscal year.

 77

(3)Compensation actually paid to our PEO consists of the following amounts deducted from or added to the Summary Compensation Table total for our CEO for each of the fiscal years presented:

    James Rolke

    Summary Compensation Table Total for Fiscal 2024
    $
    813,226

    Deduct: Stock awards(a)
     
    —

    Deduct: Option awards(b)
     
    —

    Add: Fiscal year-end value of equity awards granted during the fiscal year that are outstanding and unvested(c)
     
    —

    Add: Change in fair value of equity awards granted in prior fiscal years that are outstanding and unvested(d)
     
    —

    Add: Change in fair value of equity awards granted in prior fiscal years that vested during the fiscal year(e)
     
    —

    Add: Value of dividend equivalents accrued on equity awards during the fiscal